{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:54:53Z","timestamp":1780534493312,"version":"3.54.1"},"reference-count":54,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jaci.2024.10.020","type":"journal-article","created":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T08:12:02Z","timestamp":1730707922000},"page":"1-11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Anti-IgE and food allergy"],"prefix":"10.1016","volume":"155","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7696-1276","authenticated-orcid":false,"given":"Jennifer A.","family":"Dantzer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2024.10.020_bib1","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1542\/peds.2011-0204","article-title":"The prevalence, severity, and distribution of childhood food allergy in the United States","volume":"128","author":"Gupta","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaci.2024.10.020_bib2","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.anai.2022.11.026","article-title":"The epidemiology of food allergy in adults","volume":"130","author":"Warren","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2024.10.020_bib3","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s11882-023-01120-y","article-title":"Epidemiology and the growing epidemic of food allergy in children and adults across the globe","volume":"24","author":"Warren","year":"2024","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.jaci.2024.10.020_bib4","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.anai.2022.12.031","article-title":"The epidemiology of multifood allergy in the United States: a population-based study","volume":"130","author":"Warren","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2024.10.020_bib5","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2018-1235","article-title":"The public health impact of parent-reported childhood food allergies in the United States","volume":"142","author":"Gupta","year":"2018","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaci.2024.10.020_bib6","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s11882-020-0898-7","article-title":"Epidemiology and burden of food allergy","volume":"20","author":"Warren","year":"2020","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.jaci.2024.10.020_bib7","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1016\/j.jaip.2021.02.039","article-title":"The psychosocial burden of food allergy among adults: a US population-based study","volume":"9","author":"Warren","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2024.10.020_bib8","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1056\/NEJMoa1812856","article-title":"AR101 Oral immunotherapy for peanut allergy","volume":"379","author":"Vickery","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2024.10.020_bib10","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1056\/NEJMoa2312382","article-title":"Omalizumab for the treatment of multiple food allergies","volume":"390","author":"Wood","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2024.10.020_bib11","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.anai.2018.09.464","article-title":"Dr. Kimishige Ishizaka: 1926-2018: The discovery of IgE and the revolution in the study of allergic disease","volume":"122","author":"Platts-Mills","year":"2019","journal-title":"Ann Allergy Asthma and Immunol"},{"key":"10.1016\/j.jaci.2024.10.020_bib12","doi-asserted-by":"crossref","first-page":"849","DOI":"10.4049\/jimmunol.99.5.849","article-title":"Antigenic structure of gamma-E-globulin and reaginic antibody","volume":"99","author":"Ishizaka","year":"1967","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2024.10.020_bib13","first-page":"265","article-title":"A new class of immunoglobulin in human serum","volume":"14","author":"Johansson","year":"1968","journal-title":"Immunology"},{"key":"10.1016\/j.jaci.2024.10.020_bib14","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0140-6736(67)90615-0","article-title":"Diagnosis of allergy by an in-vitro test for allergen antibodies","volume":"2","author":"Wide","year":"1967","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2024.10.020_bib15","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/0019-2791(70)90175-8","article-title":"Biologic function of the Fc fragments of E myeloma protein","volume":"7","author":"Ishizaka","year":"1970","journal-title":"Immunochemistry"},{"key":"10.1016\/j.jaci.2024.10.020_bib16","doi-asserted-by":"crossref","first-page":"588","DOI":"10.4049\/jimmunol.103.3.588","article-title":"Immune mechanisms of reversed type reaginic hypersensitivity","volume":"103","author":"Ishizaka","year":"1969","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2024.10.020_bib17","first-page":"122","article-title":"Monoclonal antibodies specific for human IgE-producing B cells: a potential therapeutic for IgE-mediated allergic diseases","volume":"8","author":"Chang","year":"1990","journal-title":"Biotechnology (N Y)"},{"key":"10.1016\/j.jaci.2024.10.020_bib18","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1159\/000235333","article-title":"New concepts of IgE regulation","volume":"94","author":"Heusser","year":"1991","journal-title":"Int Arch Allergy Appl Immunol"},{"issue":"8\u201315","key":"10.1016\/j.jaci.2024.10.020_bib19","first-page":"19","article-title":"Drug approval highlights for 2003","volume":"29","author":"Laustsen","year":"2004","journal-title":"Nurse Pract"},{"key":"10.1016\/j.jaci.2024.10.020_bib20","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1056\/NEJMoa022613","article-title":"Effect of anti-IgE therapy in patients with peanut allergy","volume":"348","author":"Leung","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2024.10.020_bib21","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1111\/all.14308","article-title":"Past, present, and future of anti-IgE biologics","volume":"75","author":"Guntern","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2024.10.020_bib22","doi-asserted-by":"crossref","first-page":"5624","DOI":"10.4049\/jimmunol.162.9.5624","article-title":"Down-regulation of human basophil IgE and FC epsilon RI alpha surface densities and mediator release by anti-IgE-infusions is reversible in\u00a0vitro and in\u00a0vivo","volume":"162","author":"Saini","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2024.10.020_bib23","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.4049\/jimmunol.158.3.1438","article-title":"Down-regulation of Fc(epsilon)RI expression on human basophils during in\u00a0vivo treatment of atopic patients with anti-IgE antibody","volume":"158","author":"MacGlashan","year":"1997","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2024.10.020_bib25","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jaci.2011.01.051","article-title":"A phase II, randomized, double-blind, parallel-group, placebo-controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy","volume":"127","author":"Sampson","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.10.020_bib26","doi-asserted-by":"crossref","first-page":"76","DOI":"10.2500\/aap.2010.31.3304","article-title":"Effects of omalizumab in patients with food allergy","volume":"31","author":"Rafi","year":"2010","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaci.2024.10.020_bib27","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jaci.2012.05.039","article-title":"Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy","volume":"130","author":"Savage","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.10.020_bib28","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/cea.12862","article-title":"Individually dosed omalizumab: an effective treatment for severe peanut allergy","volume":"47","author":"Brandstr\u00f6m","year":"2017","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2024.10.020_bib29","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/j.jaip.2019.01.023","article-title":"Impact of omalizumab on food allergy in patients treated for asthma: a real-life study","volume":"7","author":"Fiocchi","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2024.10.020_bib30","doi-asserted-by":"crossref","DOI":"10.1111\/pai.14057","article-title":"Omalizumab in severe asthma and food allergies with IgE levels >1500 kU\/L: two-year evaluation","volume":"34","author":"Dinardo","year":"2023","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaci.2024.10.020_bib31","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/j.jaci.2011.04.009","article-title":"Rapid oral desensitization in combination with omalizumab therapy in patients with cow\u2019s milk allergy","volume":"127","author":"Nadeau","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.10.020_bib32","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.jaci.2015.10.005","article-title":"A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow\u2019s milk allergy","volume":"137","author":"Wood","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.10.020_bib33","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jaci.2013.09.046","article-title":"A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients","volume":"132","author":"Schneider","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.10.020_bib34","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jaip.2018.09.015","article-title":"Long-term outcome of peanut oral immunotherapy facilitated initially by omalizumab","volume":"7","author":"Yee","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2024.10.020_bib35","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1111\/cea.13469","article-title":"Individually dosed omalizumab facilitates peanut oral immunotherapy in peanut allergic adolescents","volume":"49","author":"Brandstr\u00f6m","year":"2019","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2024.10.020_bib36","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.jaci.2016.08.010","article-title":"Omalizumab facilitates rapid oral desensitization for peanut allergy","volume":"139","author":"MacGinnitie","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.10.020_bib37","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1710-1492-10-7","article-title":"Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using omalizumab","volume":"10","author":"B\u00e9gin","year":"2014","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaci.2024.10.020_bib38","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S2468-1253(17)30392-8","article-title":"Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial","volume":"3","author":"Andorf","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jaci.2024.10.020_bib39","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.eclinm.2018.12.006","article-title":"A phase 2 randomized controlled multisite study using omalizumab-facilitated rapid desensitization to test continued vs discontinued dosing in multifood allergic individuals","volume":"7","author":"Andorf","year":"2019","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jaci.2024.10.020_bib40","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jaci.2020.08.039","article-title":"Determinants of omalizumab dose-related efficacy in oral immunotherapy: evidence from a cohort of 181 patients","volume":"147","author":"Azzano","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.10.020_bib41","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.anai.2023.03.030","article-title":"Anti-immunoglobulin E for food allergy","volume":"131","author":"Dantzer","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2024.10.020_bib42","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.jaip.2022.11.036","article-title":"Omalizumab in IgE-mediated food allergy: a systematic review and meta-analysis","volume":"11","author":"Zuberbier","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2024.10.020_bib43","doi-asserted-by":"crossref","first-page":"AB378","DOI":"10.1016\/j.jaci.2023.11.909","article-title":"Omalizumab for the treatment of multiple food allergy (OUtMATCH)","volume":"153","author":"Wood","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.10.020_bib44","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jacig.2022.05.006","article-title":"Protocol design and synopsis: omalizumab as monotherapy and as adjunct therapy to multiallergen OIT in children and adults with food allergy (OUtMATCH)","volume":"1","author":"Wood","year":"2022","journal-title":"J Allergy Clin Immunol Global"},{"key":"10.1016\/j.jaci.2024.10.020_bib45","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1016\/j.jaip.2023.03.051","article-title":"Double-blind, placebo-controlled study of E-B-FAHF-2 in combination with omalizumab-facilitated multiallergen oral immunotherapy","volume":"11","author":"Wang","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2024.10.020_bib46","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41467-019-13815-w","article-title":"The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab","volume":"8","author":"Gasser","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2024.10.020_bib47","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/cea.12400","article-title":"Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects","volume":"44","author":"Arm","year":"2014","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2024.10.020_bib48","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1111\/all.15567","article-title":"Ligelizumab impairs IgE-binding to plasmacytoid dendritic cells more potently than omalizumab and restores IFN-\u03b1 production and FOXP3+ Treg generation","volume":"78","author":"Benito-Villalvilla","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2024.10.020_bib49","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1900408","article-title":"Ligelizumab for chronic spontaneous urticaria","volume":"381","author":"Maurer","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2024.10.020_bib50","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1255","article-title":"Ligelizumab treatment for severe asthma: learnings from the clinical development programme","volume":"10","author":"Trischler","year":"2021","journal-title":"Clin Transl Immunol"},{"key":"10.1016\/j.jaci.2024.10.020_bib51","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0140-6736(23)01684-7","article-title":"Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials","volume":"403","author":"Maurer","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2024.10.020_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2022.100690","article-title":"The rationale for development of ligelizumab in food allergy","volume":"15","author":"Wood","year":"2022","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.jaci.2024.10.020_bib53","doi-asserted-by":"crossref","DOI":"10.1172\/JCI157765","article-title":"IgE-neutralizing UB-221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23-mediated IgE downregulation and relieves urticaria symptoms","volume":"132","author":"Kuo","year":"2022","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2024.10.020_bib54","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13223-020-00419-z","article-title":"Protocol for a double-blind, randomized controlled trial on the dose-related efficacy of omalizumab in multi-food oral immunotherapy","volume":"16","author":"Langlois","year":"2020","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaci.2024.10.020_bib55","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.jaci.2024.03.019","article-title":"A practical guide for implementing omalizumab therapy for food allergy","volume":"153","author":"Casale","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.10.020_bib56","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1016\/j.jaip.2024.04.053","article-title":"Patient-reported outcome measures in food and drug allergy","volume":"12","author":"Anagnostou","year":"2024","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674924011643?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674924011643?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T19:50:15Z","timestamp":1750708215000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674924011643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0091674924011643"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2024.10.020","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-IgE and food allergy","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2024.10.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}